Monopar Net Interest Income vs Net Income Analysis

MNPR Stock  USD 34.65  5.45  13.59%   
Monopar Therapeutics financial indicator trend analysis is infinitely more than just investigating Monopar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monopar Therapeutics is a good investment. Please check the relationship between Monopar Therapeutics Net Interest Income and its Net Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

Net Interest Income vs Net Income

Net Interest Income vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monopar Therapeutics Net Interest Income account and Net Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Monopar Therapeutics' Net Interest Income and Net Income is -0.82. Overlapping area represents the amount of variation of Net Interest Income that can explain the historical movement of Net Income in the same time period over historical financial statements of Monopar Therapeutics, assuming nothing else is changed. The correlation between historical values of Monopar Therapeutics' Net Interest Income and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Interest Income of Monopar Therapeutics are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Net Interest Income i.e., Monopar Therapeutics' Net Interest Income and Net Income go up and down completely randomly.

Correlation Coefficient

-0.82
Relationship DirectionNegative 
Relationship StrengthSignificant

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Monopar Therapeutics financial statement analysis. It represents the amount of money remaining after all of Monopar Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from Monopar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.At this time, Monopar Therapeutics' Selling General Administrative is relatively stable compared to the past year. As of 08/08/2025, Issuance Of Capital Stock is likely to grow to about 62.4 M, while Tax Provision is likely to drop (67.7 K).
 2022 2023 2024 2025 (projected)
Interest Income21.2K343.6K404.0K424.2K
Net Interest Income21.2K343.6K404.0K424.2K

Monopar Therapeutics fundamental ratios Correlations

0.960.960.56-0.99-0.950.540.990.961.00.020.10.960.941.00.930.570.740.980.98-0.06-0.510.9-0.91-0.91
0.961.00.35-0.91-1.00.380.921.00.95-0.230.011.00.880.950.970.350.580.980.98-0.22-0.670.95-0.95-0.95
0.961.00.35-0.91-1.00.380.921.00.95-0.230.011.00.880.950.970.350.580.980.98-0.22-0.670.95-0.95-0.95
0.560.350.35-0.63-0.370.910.610.350.570.740.20.350.690.570.430.980.930.410.430.440.360.43-0.25-0.25
-0.99-0.91-0.91-0.630.91-0.56-1.0-0.91-0.99-0.1-0.15-0.91-0.91-0.99-0.89-0.64-0.79-0.96-0.960.040.44-0.880.850.85
-0.95-1.0-1.0-0.370.91-0.39-0.92-1.0-0.950.23-0.01-1.0-0.88-0.95-0.97-0.36-0.6-0.98-0.980.240.67-0.960.930.93
0.540.380.380.91-0.56-0.390.540.380.550.60.090.380.760.550.440.860.880.410.430.460.330.43-0.3-0.3
0.990.920.920.61-1.0-0.920.540.920.990.080.150.920.910.990.90.620.760.960.97-0.02-0.460.87-0.88-0.88
0.961.01.00.35-0.91-1.00.380.920.95-0.230.011.00.880.950.970.350.580.980.98-0.22-0.670.95-0.95-0.95
1.00.950.950.57-0.99-0.950.550.990.950.030.110.950.941.00.930.580.750.980.98-0.05-0.50.9-0.91-0.91
0.02-0.23-0.230.74-0.10.230.60.08-0.230.030.45-0.230.160.03-0.120.790.46-0.18-0.160.680.72-0.210.220.22
0.10.010.010.2-0.15-0.010.090.150.010.110.450.010.050.110.00.320.030.010.020.040.030.0-0.01-0.01
0.961.01.00.35-0.91-1.00.380.921.00.95-0.230.010.880.950.970.350.580.980.98-0.22-0.670.95-0.95-0.95
0.940.880.880.69-0.91-0.880.760.910.880.940.160.050.880.940.890.660.830.890.890.15-0.290.83-0.84-0.84
1.00.950.950.57-0.99-0.950.550.990.951.00.030.110.950.940.930.580.740.980.98-0.05-0.50.9-0.91-0.91
0.930.970.970.43-0.89-0.970.440.90.970.93-0.120.00.970.890.930.420.640.930.93-0.07-0.530.92-0.92-0.92
0.570.350.350.98-0.64-0.360.860.620.350.580.790.320.350.660.580.420.890.410.430.430.330.4-0.26-0.26
0.740.580.580.93-0.79-0.60.880.760.580.750.460.030.580.830.740.640.890.640.650.280.130.65-0.46-0.46
0.980.980.980.41-0.96-0.980.410.960.980.98-0.180.010.980.890.980.930.410.641.0-0.18-0.630.93-0.93-0.93
0.980.980.980.43-0.96-0.980.430.970.980.98-0.160.020.980.890.980.930.430.651.0-0.17-0.620.93-0.93-0.93
-0.06-0.22-0.220.440.040.240.46-0.02-0.22-0.050.680.04-0.220.15-0.05-0.070.430.28-0.18-0.170.75-0.370.040.04
-0.51-0.67-0.670.360.440.670.33-0.46-0.67-0.50.720.03-0.67-0.29-0.5-0.530.330.13-0.63-0.620.75-0.630.640.64
0.90.950.950.43-0.88-0.960.430.870.950.9-0.210.00.950.830.90.920.40.650.930.93-0.37-0.63-0.8-0.8
-0.91-0.95-0.95-0.250.850.93-0.3-0.88-0.95-0.910.22-0.01-0.95-0.84-0.91-0.92-0.26-0.46-0.93-0.930.040.64-0.81.0
-0.91-0.95-0.95-0.250.850.93-0.3-0.88-0.95-0.910.22-0.01-0.95-0.84-0.91-0.92-0.26-0.46-0.93-0.930.040.64-0.81.0
Click cells to compare fundamentals

Monopar Therapeutics Account Relationship Matchups

Monopar Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets16.9M20.5M13.2M7.3M60.3M63.3M
Total Current Liabilities1.2M1.6M3.1M1.8M5.3B5.5B
Total Stockholder Equity15.7M18.9M10.1M5.6M55.0B57.8B
Net Tangible Assets6.9M12.6M15.7M18.9M21.8M10.9M
Net Debt(16.7M)(20.3M)(8.2M)(7.3M)(45.8M)(43.5M)
Retained Earnings(32.2M)(41.3M)(51.8M)(60.2M)(75.8B)(72.0B)
Accounts Payable1.2M1.6M3.1M1.8M2.3M1.3M
Cash16.7M20.3M8.2M7.3M45.8M48.1M
Non Current Assets Total68.9K0.061.2K12.6K60.2B63.2B
Cash And Short Term Investments16.7M20.3M13.1M7.3M60.2M63.2M
Common Stock Shares Outstanding11.0M12.5M12.7M14.5M3.8M3.6M
Liabilities And Stockholders Equity16.9M20.5M13.2M7.3M60.3M63.3M
Other Current Assets62.7K217.7K46.0K66.4K78.9K88.2K
Other Stockholder Equity47.9M60.2M61.9M65.8M130.8B137.4B
Total Liab1.2M1.6M3.1M1.8M5.3M5.5M
Total Current Assets16.8M20.5M13.2M7.3M60.3M63.3M
Accumulated Other Comprehensive Income(7.9K)(3.2K)8.9K(14.1K)36.0K37.8K
Other Current Liab1.2M1.6M(48.6K)1.8B5.3B5.5B
Net Invested Capital15.7M18.9M10.1M5.6M55.0M57.8M
Net Working Capital15.6M18.9M10.0M5.6M55.0M57.8M
Common Stock11.5K12.6K12.9K14.9K6.1K12.0K
Capital Stock11.5K12.6K12.9K14.9K6.1K5.8K

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.